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Abstract – Heterospirocyclic 3-amino-2H-azirines with a tetrahydropyran (Thp), 
tetrahydrothiopyran (Tht), or N-protected piperidine (Pip) moiety are useful 
reagents for the preparation of peptides containing the corresponding 
six-membered heterocyclic 4-amino-4-carboxylic acid unit. In the present study, 
tripeptides of the type H-Asp-D-Ala-Xaa-OMe, where Xaa is the heterocyclic 
amino acid, were prepared according to the ‘azirine/oxazolone method’. 
INTRODUCTION  
The so-called ‘azirine/oxazolone method’2 is a convenient approach for the synthesis of peptides 
containing α,α-disubstituted α-amino acids, e.g., α-aminoisobutyric acid (peptaibols).3 The utility of the 
2,2-dimethyl-substituted 3-amino-2H-azirine 1a in the preparation of such peptides has been 
demonstrated in a long series of publications.4 A special type of α,α-dialkylated α-amino acids are five- 
and six-membered heterocyclic n-amino-n-carboxylic acids,5,6 and their synthons in the method 





1c  X = NBoc
1d  X = O









Figure 1. 3-Amino-2H-azirines as synthons for α-aminoisobutyric acid (Aib, 1a) and heterocyclic 
n-amino-n-carboxylic acids (1b–e) 
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In a recent publication, we have shown that 3-amino-2H-azirines 1c–e are useful synthons for the 
preparation of tripeptides of type 4 (Scheme 1), which can be used further for the synthesis of larger 
peptides.8 The first reaction step is the azirine coupling with an N-protected amino acid 2, followed by a 
selective hydrolysis of the terminal amide function and the second coupling with an amino acid ester 3 via 































Scheme 1. Synthesis of tripeptides of type 4 (Z = benzyloxycarbonyl) 
 
An interesting type of tripeptides containing α,α-disubstituted α-amino acids are 
L-aspartyl-D-alanyl-ACnC-OMe derivatives, with ACnC = 1-aminocycloalkane-1-carboxylic acids, which 
have been studied as potential peptide sweeteners by Goodman and coworkers.9 For example, it was 
shown that the taste of the tripeptides with the six-membered and smaller carbocyclic amino acids is 
sweet, whereas the analogues with larger carbocyclic rings taste bitter. The goal of the present study was 
the synthesis of analogous tripeptides containing a heterocyclic six-membered 4-amino-4-carboxylic acid 
by using heterospirocyclic 3-amino-2H-azirines of type 1c–e as amino acid synthons. 
RESULTS AND DISCUSSION 
Whereas the syntheses of the heterospirocyclic 3-amino-2H-azirines 1c–e were carried out under standard 
conditions,7c the preparation of analogues of 1c with a benzyloxycarbonyl (Z) or allyloxycarbonyl (Alloc) 
protecting group failed. With the intention to have in hand also a synthon for 
4-aminopiperidine-4-carboxylic acid with a benzyloxycarbonyl-type of protecting group, we prepared the 
3’,5’-dimethoxy-1,1-dimethylbenzyloxycarbonyl (Ddz)-protected azirine 1f (Scheme 2). Thus, the 
reaction of the azide 510 with N-methyl-N-phenylpiperidine-4-carboxamide hydrochloride (6) in 
CH2Cl2/Et3N at room temperature gave the Ddz-protected amide 7 in 96% yield. Stepwise reaction of the 
latter with LDA, diphenyl chlorophosphate (DPPCl), and NaN3 according to our previously described 
protocol7b,11 led to the desired azirine 1f in 76% yield.  
 





























1) LDA, THF, 0 °C, 2 h
2) DPPCl, THF, 0 °C to rt, 24 h




Scheme 2. Synthesis of the Ddz-protected heterospirocyclic 3-amino-2H-azirine 1f 
 
Similar to other 2H-azirines of type 1, the new derivative 1f is a stable compound, which can be stored in 
the refrigerator for long time. Furthermore, its reactivity towards acidic compounds is analogous to that of 
1a–e. For example, the reaction with thiobenzoic acid in CH2Cl2 at room temperature
11 gave the 
















8 (79%)  
Scheme 3. Reaction of 3-amino-2H-azirine 1f with thiobenzoic acid 
 
The reaction of the heterospirocyclic 3-amino-2H-azirines 1d–f with Z- or Fmoc-protected D-alanine 
(D-Ala) under the standard conditions of the ‘azirine coupling’ (MeCN, rt) led to the enantiomerically 
pure (NMR) dipeptide amides 10a–d in 85–95% yield (Scheme 4, Table 1). In analogy to the selective 
hydrolysis of peptide amides of type 10, treatment of 10a,b with HCl gas in MeOH at rt to ca. 60 °C gave 
the dipeptide methyl esters 11a,b in excellent yields without loss of stereochemical purity. In the case of 
the piperidine derivative 10c, the Ddz-protecting group was also removed, and the methyl ester 11c with 
the free NH group in the heterocycle was obtained in 68% yield. Subsequent deprotection of the terminal 
amino group of 11a,b by hydrogenolysis or treatment with piperidine in CH2Cl2, respectively, yielded the 
desired dipeptide methyl esters 12a,b in good yields. 













































Scheme 4. Synthesis of dipeptide esters 12 via ‘azirine coupling’ (see also Table 1) 
 
Table 1. Synthesis of H-Asp-D-Ala-Xaa-OMe tripeptides 15 via the ‘azirine/oxazolone method’ 
 































































































a) Yield of isolated product. b) The dipeptide ester with the deprotected piperidine ring (X = NH) was 
obtained. c) X = N(Fmoc), P = Z; obtained from 11c. d) X = N(Boc), P = Z; obtained from 11d. e) X = 
N(Z), P = Fmoc; obtained from 10d. f) X = N(Boc), P1 = Z, P2 = Bn. g) X = N(Z), P1 = Fmoc, P2 = tBu.  
h) X = N(Boc). i) X = N(Z). j) Not obtained in pure form. 
 
With the aim of obtaining dipeptide methyl esters of type 11 with a N-protected piperidine moiety, 11c 
was treated with Fmoc-chloride and Et3N in CH2Cl2 at rt to give Z-D-Ala-Pip(Fmoc)-OMe (11d) in 87% 
yield (Table 1). The same product could be prepared from 10c in an analogous manner without isolation 
of the intermediate 11c (76% yield). Furthermore, the exchange of the Fmoc against the Boc protecting 
group was performed by subsequent treatment of 11d with piperidine in CH2Cl2 followed by 
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Boc-anhydride (Boc)2O)/Et3N to give Z-D-Ala-Pip(Boc)-OMe (11e). Similarly, Fmoc-D-Ala-Pip(Z)-OMe 
(11f) was obtained from 10d via acid-catalyzed methanolysis and treatment of the crude product with 
Et3N and Z-chloride (76% yield).  
Unfortunately, the isolated deprotected dipeptides 12a,b were not soluble in suitable solvents for peptide 
coupling. For this reason, the coupling with the diprotected aspartic acid derivatives Z-Asp(OBn)-OH 
(13a) and Fmoc-Asp(OtBu)-OH (13b), respectively, were carried out with the crude materials 12a,b. 
Thus, 11a was deprotected hydrogenolytically in DMF/MeOH, the catalyst was removed by filtration and 
MeOH evaporated. Then, 13a, Et3N, and PyBOP as the coupling reagent were added, and after 16 h the 
tripeptide 14a was obtained in 80% yield (Scheme 5, Table 1). In an analogous manner, 11e was coupled 
with 13a to give the fully protected Z-Asp(OBn)-D-Ala-Pip(Boc)-OMe (14c) in 84% yield. Both 














13a  P1 = Z, P2 = Bn


























Scheme 5. Synthesis of tripeptide methyl esters 15 (H-Asp-D-Ala-Xaa-OMe; see also Table 1) 
 
The Fmoc-protected dipeptides 11b,f were deprotected by treatment with piperidine in DMSO at rt. After 
evaporation of piperidine, 13b and PyBOP were added, and after stirring at rt for 16 h and 
chromatographic purification, 14b and 14d were isolated in 92 and 44% yield, respectively. The 
deprotection to give 15b,d was achieved in two steps: removal of the Fmoc group with piperidine in 
CH2Cl2 at rt and subsequent cleavage of the tert-butyl ester by treatment with trifluoroacetic acid (TFA). 
Whereas the partially deprotected tripeptides H-Asp(OtBu)-D-Ala-Tht-OMe and 
H-Asp(OtBu)-D-Ala-Pip(Z)-OMe were obtained in pure forms, the desired zwitterionic compounds 15b,d 
were still contaminated with small amounts of impurities, which could not be removed. 
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CONCLUSIONS 
The heterospirocyclic 3-amino-2H-azirines 1d–f were shown to be convenient starting materials for the 
synthesis of peptides containing saturated six-membered heterocyclic 4-amino-4-carboxylic acids. In 
addition to the previously described 1d and 1e containing a tetrahydropyran and tetrahydrothiopyran ring, 
respectively, the new synthon 1f, a 1,6-diazaspiro[2.5]oct-1-ene derivative with a Ddz-protected 
piperidine moiety, was used for the ‘azirine coupling’ with N-protected D-alanine to give the 
corresponding dipeptide amides in high yields. The Ddz protecting group can be removed easily under 
acidic conditions allowing the smooth exchange of the protecting group. The terminal amide function of 
the dipeptides with a heterocyclic α-amino carboxylic acid was transformed into the corresponding 
methyl ester via selective methanolysis. Deprotection of the N-terminus and coupling with asparagine 
derivatives leads to the fully protected tripeptide esters of type P1-Asp(P2)-D-Ala-Xaa-OMe. The 
deprotection of the examples with hydrogenolytically removable groups was achieved successfully to 
give the zwitterionic tripeptide esters, which are analogues of those with a carbocyclic α-amino 
carboxylic acid. It is worth mentioning that the taste of tripeptide 15a with a tetrahydropyran moiety is 
sweet, similar to the cyclohexane analogue,9 whereas that of 15c with a Boc-protected piperidine ring is 
bitter. 
EXPERIMENTAL 
General remarks. Melting points were determined using a Mettler FP5 apparatus, and they are 
uncorrected. Thin layer chromatography (TLC): Merck silica gel 60 F254 plates (0.25 mm); column 
chromatography (CC): silica gel Merck 60 (0.040–0.063 mm. The IR spectra were recorded on a 
Perkin-Elmer 297 or Perkin-Elmer 781 spectrophotometer in CDCl3 or in KBr; absorptions in cm
–1. The 
1H- and 13C-NMR spectra were measured on a Bruker ARX-300, AM-400 or AMX-600 instrument 
(300/75.4, 400/100.6, and 600/150.9 MHz, resp.) in CDCl3 with TMS as internal standard. Chemical 
shifts (δ) are given in ppm and coupling constants J in Hz. Mass spectra (MS) were recorded on a 
Finnigan SSQ-700 (CI, NH3, 150 eV) or Finnigan TSQ-700 (ESI) instrument. Optical rotations [αD]: 
Zeiss LEP-A2 polarimeter, in MeOH at 20–22 ºC.  
 
Starting materials. The synthesis of N-methyl-N-phenyl-6-oxa-1-azaspiro[2.5]oct-1-en-2-amine (1d) 
and N-methyl-N-phenyl-6-thia-1-azaspiro[2.5]oct-1-en-2-amine (1e) has been described previously.7b The 
amino acid derivatives Z- and Fmoc-D-Ala (9a,b) and Z, Bn- and Fmoc, tBu-protected Asp as well as all 
used reagents were commercially available. Reported yields refer to isolated pure products. 
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Abbreviations. AcOEt, ethyl acetate; D-Ala, D-alanine; Alloc, allyloxycarbonyl; Asp, aspartic acid; Bn, 
benzyl; Boc, tert-butyloxycarbonyl; CC, column chromatography; Ddz, 
3’,5’-dimethoxy-1,1-dimethylbenzyloxycarbonyl; DMF, N,N-dimethylformamide; DPPCl, diphenyl 
chlorophosphate; Et2O, diethyl ether; Fmoc, fluorenylmethyloxycarbonyl; LDA, lithium 
diisopropylamide; MeCN, acetonitrile; Pip, 4-aminopiperidine-4-carboxylic acid; PyBOP, 
[(benzotriazol-1-yl)oxy]tripyrrolidinophosphonium hexafluorophosphate; THF, tetrahydrofuran; Thp, 
4-aminotetrahydropyran-4-carboxylic acid; Tht, 4-aminotetrahydrothiopyran-4-carboxylic acid; Z, 
benzyloxycarbonyl. 
 
Synthesis of 6-[(3’,5’-dimethoxy-1,1-dimethylbenzyloxy)carbonyl]-2-(N-methyl-N-phenylamino)- 
1,6-diazaspiro[2.5]oct-1-ene (1f). 1-[(3’,5’-Dimethoxy-1,1-dimethylbenzyloxy)carbonyl]piperidine-4- 
(N-methyl-N-phenylcarboxamide) (7). To a stirred solution of 9.86 g (38.7 mmol) 
piperidine-4-(N-methyl-N-phenylcarboxamide) hydrochloride (6) in CH2Cl2 (100 mL) at 0 °C were added 
Et3N (12 mL, 86 mmol) and (3’,5’-dimethoxy-1,1-dimethylbenzyloxy)carbonyl azide
10 (5; 11.3 g, 42.6 
mmol). After 1 h at rt, the mixture was washed with aqueous Na2CO3 solution (10%, 2×), and the aqueous 
solutions were extracted with CH2Cl2. The combined organic phases were dried (Na2SO4) and the solvent 
evaporated. CC (hexane/AcOEt 1:2) and recrystallization from CH2Cl2 gave 16.5 g (96%) of 7. Colorless 
crystals; mp 125–126 °C. IR (CHCl3): 3460w, 3020w, 3000m, 2950m, 2860w, 2840w, 1680s, 1645s, 
1600s, 1495m, 1470m, 1455m, 1430s, 1390m, 1350m, 1310m, 1300m, 1285m, 1270m, 1220m, 1160s, 
1135m, 1070m, 1050m, 1025m, 965w, 935w, 890w, 845w, 835w. 1H-NMR ((D6)DMSO, 85 °C): 
7.47–7.26, 6.44–6.43, 6.36–6.34 (3m, 8 arom. H); 3.97–3.68 (dt-like, 2 H of –CH2NCH2–); 3.73 (s, 2 
MeO); 3.16 (s, MeN); 2.62–2.40 (m, 2 H of –CH2NCH2–, CH(4)); 1.66 (s, Me2C); 1.61–1.44 (m, 
–CH2CCH2–). 
13C-NMR ((D6)DMSO, 85 °C): 173.1 (s, C=O); 160.6 (s, 2 arom. COMe); 152.6, 148.4, 
143.5 (3s, OCON, 2 arom. C); 129.1, 126.9, 126.6, 102.6, 98.2 (5d, 8 arom. CH); 79.9 (s, Me2CO); 54.7 
(q, 2 MeO); 42.4 (t, –CH2NCH2–); 37.8 (d, CH(4)); 36.6 (q, MeN); 28.2 (q, Me2C); 27.7 (t, –CH2CCH2–). 
ESI-MS: 463 (100, [M+Na]+), 241 (36). Anal. Calcd for C25H32N2O5 (440.54): C 68.16, H 7.32, N 6.36. 
Found: C 68.18, H 7.32, N 6.40. 
 
6-[(3’,5’-Dimethoxy-1,1-dimethylbenzyloxy)carbonyl]-2-(N-methyl-N-phenylamino)-1,6-diazaspiro- 
[2.5]oct-1-ene (1f). To a solution of 7 (7.00 g, 15.9 mmol) in THF (40 mL) at 0 °C under Ar atmosphere 
was added a 1.5M solution of LDA in cyclohexane (9.5 mL, 19 mmol), and the mixture was stirred at 
0 °C for 90 min. Then, DPPCl (4.72 g, 17.6 mmol) was added by means of a syringe at 0 °C, the solution 
stirred at 0 °C for 30 min and at rt for 24 h. The formed precipitate was filtered of under Ar atmosphere, 
the filtrate was added to 3.12 g (47.9 mmol) NaN3 and the mixture stirred at rt for 3 d. After addition of 
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Et2O and filtration of the mixture on Celite, the solvents of the filtrate were evaporated, the residue 
dissolved in CH2Cl2 and washed with aqueous NaHCO3 (5%, 3×). The combined aqueous phases were 
washed with CH2Cl2, the combined organic phases were dried (MgSO4), and the solvent evaporated. 
Purification via CC (SiO2, hexane/AcOEt 2:1) gave 5.31 g (76%) of the azirine 1f. Colorless, viscous oil. 
IR (CHCl3): 3000m, 2970m, 2940m, 2860w, 2840w, 1750s, 1685s, 1600s, 1500m, 1460s, 1425s, 1380w, 
1365m, 1350m, 1320m, 1300m, 1275m, 1250m, 1155s, 1100s, 1070m, 1020m, 960w, 890w, 835w, 695w, 
610w. 1H-NMR ((D6)DMSO, 85 °C): 7.45–7.33, 7.16–7.10, 6.52–6.51, 6.41–6.39 (4m, 8 arom. H); 
3.78–3.70 (m, 2 H of –CH2NCH2–); 3.76 (s, 2 MeO); 3.52–3.42 (m, 2 H of –CH2NCH2–); 3.43 (s, MeN); 
1.95–1.84 (m, 2 H of –CH2CCH2–); 1.74 (s, Me2C); 1.42–1.34 (m, 2 H of –CH2CCH2–). 
13C-NMR 
((D6)DMSO, 85 °C): 165.7, 160.0, 152.9, 148.8, 142.1 (5s, C(2), 2 arom. COMe, OCON, 2 arom. C); 
128.7, 122.7, 116.8, 102.7, 98.1 (5d, 8 arom. CH); 80.1 (s, Me2CO); 54.7 (q, 2 MeO); 42.5 (t, 
–CH2NCH2–); 35.1 (q, MeN); 34.2 (t, –CH2CCH2–); 28.2 (q, Me2C); C(3) could not be detected. ESI-MS: 
439 (28), 438 (100, [M+1]+), 260 (34), 179 (25).  
 
Reaction of azirine 1f with thiobenzoic acid. Synthesis of N-{1-[(3’,5’-dimethoxy-1,1-dimethyl- 
benzyloxy)carbonyl]-4-(N-methyl-N-phenylthiocarbamoyl)piperidin-4-yl}benzamide (8). To a 
solution of 1f (428 mg, 0.978 mmol) in CH2Cl2 (2 mL) at 0 °C was added a solution of thiobenzoic acid 
(152 mg, 1.10 mmol) in 2 mL of CH2Cl2. After stirring for 14 h at rt, the solvent was evaporated and the 
residue was purified by CC to give 453 mg (79%) of 8 as a yellow foam. IR (CHCl3): 3450w, 3020w, 
3000m, 2940m, 2860w, 2840w, 1690s, 1680s, 1630w, 1600s, 1510m, 1485m, 1460m, 1430s, 1365m, 
1350m, 1320m, 1285m, 1255m, 1180w, 1160s, 1140m, 1110m, 1090m, 1070m, 1030w, 1000w, 975w, 
960w, 925w, 885w, 835w. 1H-NMR ((D6)DMSO, 97 °C): 7.74–7.70, 7.54–7.37, 7.27–7.12 (3m, 10 arom. 
H, 1 NH); 6.49–6.48, 6.39–6.38 (2m, 3 arom. H); 3.87–3.79 (m, 2 H of –CH2NCH2–); 3.75 (s, 2 MeO); 
3.61 (s, MeN); 3.18–3.07 (m, 2 H of –CH2NCH2–); 2.56–2.39 (m, –CH2CCH2–); 1.71 (s, Me2C). 
13C-NMR ((D6)DMSO, 97 °C): 207.8 (s, C=S); 165.3 (s, C=O); 160.0 (s, 2 arom. COMe); 152.8 (s, 
OCON); 148.7, 147.9, 134.0 (3s, 3 arom. C); 130.5, 128.7, 127.3, 126.9, 126.6, 125.1 (6d, 10 arom. CH); 
102.7, 98.2 (2d, 3 arom. CH); 80.0 (s, Me2CO); 63.1 (s, C(4’)); 54.7 (q, 2 MeO); 48.6 (q, MeN); 39.3 (t, 
–CH2NCH2–); 35.0 (t, –CH2CCH2–); 28.1 (q, Me2C). ESI-MS: 598 (100, [M+Na]
+). 
 
General procedure for the synthesis of dipeptide amides 10a–d (azirine coupling). To a solution of 
the corresponding azirine 1 in MeCN, THF or CH2Cl2 at 0 °C, Z- or Fmoc-protected D-Ala was added and 
the mixture stirred at rt for 16 h. After evapration of the solvent, the residue was purified by CC. 
Z-D-Ala-Thp-N(Ph)Me (10a). The reaction of 400 mg (1.85 mmol) of azirine 1d and 457 mg (2.05 
mmol) of Z-D-Ala-OH in MeCN (4 mL) followed by CC (Et2O/AcOEt 1:1) gave 746 mg (92%) of 10a. 
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Colorless solid; mp 103–105 °C. IR (CHCl3): 3520m, 3330w, 3070w, 3030w, 3000m, 2960m, 2930w, 
2860w, 1690s, 1640s, 1595m, 1500s, 1470w, 1450m, 1430w, 1370m, 1350m, 1320m, 1290m, 1230m, 
1170w, 1150w, 1110m, 1070m, 1030w, 1000w, 980w, 960w, 910w, 880w, 860w, 825w, 700m. 1H-NMR 
(CDCl3): 7.37–7.29, 7.14–7.12 (2m, 10 arom. H); 5.95 (s, 1 NH); 5.19 (d, J = 7.1, 1 NH); 5.10, 5.04 (2d, 
JAB = 12.3, PhCH2O); 3.74–3.62, 3.40–3.24 (2m, HC(2) of Ala, –CH2OCH2–); 3.21 (s, MeN); 2.33–2.25, 
1.96–1.91 (2m, –CH2CCH2–); 1.26 (d, J = 7.0, Me of Ala). 
13C-NMR (CDCl3): 171.3, 170.8 (2s, 2 C=O); 
156.1 (s, OCON); 144.7, 135.9 (2s, 2 arom. C); 129.5, 128.5, 128.3, 128.0, 127.8, 127.2 (6d, 10 arom. 
CH); 67.2, 63.0, 62.9 (3t, PhCH2O, –CH2OCH2–); 58.1 (s, C(4’)); 50.1 (d, HC(2) of Ala); 41.4 (q, MeN); 
33.7, 33.1 (2t, –CH2CCH2–); 17.2 (q, Me of Ala). ESI-MS: 901 (47, [2M+Na]
+), 462 (100, [M+Na]+). 
[α21D] +20.6 (c 1.003).  
Fmoc-D-Ala-Tht-N(Ph)Me (10b). The reaction of 500 mg (2.15 mmol) of azirine 1e and 737 mg (2.34 
mmol) of Z-D-Ala-OH in THF (5 mL) followed by CC (hexane/AcOEt 1:2) gave 1074 mg (92%) of 10b. 
Colorless solid; mp 130–132 °C. IR (CHCl3): 3420m, 3340m, 3000m, 2960m, 1690s, 1640s, 1595m, 
1495s, 1465w, 1450m, 1430w, 1370m, 1350w, 1320m, 1280m, 1250m, 1170w, 1130w, 1105w, 1070m, 
1040w, 975w. 1H-NMR (CDCl3): 7.76, 7.56 (2d, J = 7.4, 4 Fmoc-H); 7.39 (d, J = 7.4, 2 Fmoc-H); 
7.33–7.25, 7.14–7.11 (2m, 7 arom. H); 5.95 (s, 1 NH); 5.22 (d, J = 7.6, 1 NH); 4.44–4.32 (m, Fmoc-CH2); 
4.20 (t, J = 6.6, Fmoc-C(9)H); 3.60 (quint, J = 7.2, HC(2) of Ala); 3.21 (s, MeN); 2.69–2.65, 2.52–2.24 
(2m, 4 CH2); 1.24 (d, J = 7.1, Me of Ala). 
13C-NMR (CDCl3): 171.7, 170.8 (2s, 2 C=O); 156.2 (s, 
OCON); 144.9, 143.7, 143.5, 141.3 (4s, 5 arom. C); 129.5, 127.8, 127.2, 127.1, 124.8, 120.1 (6d, 13 arom. 
CH); 67.2 (t, Fmoc-CH2); 59.7 (s, C(4’)); 50.0 (d, HC(2) of Ala); 47.0 (d, Fmoc-C(9)H); 41.5 (q, MeN); 
34.2, 33.7 (2t, –CH2CCH2–); 23.1, 22.9 (2t, –CH2SCH2–); 17.3 (q, Me of Ala). ESI-MS: 566 (100, 
[M+Na]+). [α21D] +22.2 (c 0.962).  
Z-D-Ala-Pip(Ddz)-N(Ph)Me (10c). The reaction of 536 mg (1.23 mmol) of azirine 1f and 295 mg (1.36 
mmol) of Z-D-Ala-OH in CH2Cl2 (10 mL) led to analytically pure crystalline 10c (771 mg, 95%). 
Colorless powder; mp 150–152 °C. IR (KBr): 3430m, 3060w, 3000w, 2980m, 2930m, 2880w, 2830w, 
1715s, 1690s, 1670s, 1650m, 1640w, 1630w, 1610s, 1590s, 1545m, 1540m, 1525m, 1495m, 1470m, 
1455m, 1415m, 1380m, 1360m, 1315m, 1300m, 1285m, 1275m, 1255s, 1205m, 1155m, 1140m, 1100m, 
1070m, 1050s, 1035m, 1025m, 995w, 965w, 940m, 845m, 770m, 740m, 730m, 700m. 1H-NMR 
((D6)DMSO): 7.86 (s, 1 NH); 7.35–7.27 (m, 10 arom. H); 7.15 (d, J = 7.3, 1 NH); 6.34–6.42, 6.38–6.36 
(2m, 3 arom. H); 5.09, 5.01 (2d, JAB = 12.6, PhCH2O); 4.02–3.50 (m, HC(2) of Ala, 2 H of –CH2NCH2–); 
3.72 (s, 2 MeO); 3.25–2.75 (m, 2 H of –CH2NCH2–); 3.18 (s, MeN); 2.11–1.58 (m, –CH2CCH2–); 1.67 (s, 
Me2C); 1.20 (d, J = 7.1, Me of Ala). 
13C-NMR ((D6)DMSO): 171.7, 171.2 (2s, 2 C=O); 160.2 (s, 2 arom. 
COMe); 155.6, 152.9 (2s, 2 OCON); 149.1, 145.1, 137.0 (3s, 3 arom. C); 128.9, 128.2, 127.7, 127.5, 
127.2, 126.7 (6d, 10 arom. CH); 102.6, 97.9 (2d, 2 arom. CH); 80.2 (s, Me2CO); 65.2 (t, PhCH2O); 57.3 
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(s, C(4’)); 55.0 (q, 2 MeO); 50.7 (d, HC(2) of Ala); 39.9 (q, MeN); 39.7, 39.2 (2t, –CH2NCH2–); 32.0, 
31.4 (2t, –CH2CCH2–); 28.9, 28.5 (2q, Me2C); 18.3 (q, Me of Ala). ESI-MS: 683 (100, [M+Na]
+). Anal. 
Calcd for C36H44N4O8 (660.77): C 65.44, H 6.71, N 8.48. Found: C 65.33, H 6.71, N 8.31. 
Fmoc-D-Ala-Pip(Ddz)-N(Ph)Me (10d). The reaction of 860 mg (1.97 mmol) of azirine 1f and 617 mg 
(1.98 mmol) of Fmoc-D-Ala-OH in CH2Cl2 (10 mL) followed by CC (hexane/AcOEt 1:2) gave 1249 mg, 
85%) of 10d. Colorless powder; mp 170–171 °C. IR (KBr): 3440m, 3060w, 2980m, 2940m, 2880w, 
2830w, 1710s, 1695s, 1685s, 1675s, 1615s, 1590s, 1540m, 1530s, 1500m, 1470m, 1450m, 1430m, 1415s, 
1380m, 1365w, 1315m, 1300m, 1280m, 1235s, 1205m, 1195m, 1160m, 1130m, 1100m, 1070m, 1050m, 
1030m, 1000w, 980w, 975w, 940m, 850m, 770m, 740m, 760m, 740m, 700m. 1H-NMR ((D6)DMSO): 7.85, 
7.69 (2d, J = 7.4, 4 Fmoc-H); 7.44–7.14 (m, 9 arom. H, 1 NH); 6.86 (d, J = 7.9, 1 NH); 6.49–6.46, 
6.40–6.36 (2m, 3 arom. H); 4.43–4.21 (m, Fmoc-CH2, HC(2) of Ala); 4.04–4.34 (m, Fmoc-C(9)H); 3.75 
(s, 2 MeO); 3.74–3.50 (m, 2 H of –CH2NCH2–); 3.20 (s, MeN); 3.25–3.07 (m, 2 H of –CH2NCH2–); 
2.15–1.97 (m, –CH2CCH2–); 1.70 (s, Me2C); 1.25 (d, J = 7.0, Me of Ala). 
13C-NMR ((D6)DMSO): 172.1, 
171.7 (2s, 2 C=O); 160.6 (s, 2 arom. COMe); 156.1, 153.4 (2s, 2 OCON); 149.5, 145.5, 144.2, 141.1 (4s, 
6 arom. C); 129.3, 128.0, 127.6, 127.4, 127.1, 125.7, 120.4, 103.0, 98.3 (9d, 16 arom. CH); 80.6 (s, 
Me2CO); 66.0 (t, Fmoc-CH2); 57.7 (s, C(4’)); 55.4 (q, 2 MeO); 50.1, 47.0 (2d, HC(2) of Ala, 
Fmoc-C(9)H); 40.0 (q, MeN); 39.3, 38.5 (2t, –CH2NCH2–); 32.6, 31.9 (2t, –CH2CCH2–); 29.5, 28.8 (2q, 
Me2C); 18.8 (q, Me of Ala). ESI-MS: 771 (100, [M+Na]
+).  
 
General procedure for the selective methanolysis of dipeptide amides 10a–d. The corresponding 
dipeptide amide 10 was dissolved in MeOH at 0 °C, and HCl gas was bubbled through the solution until it 
reached ca. 60 °C. Then, the mixture was stirred for 2 h at rt, 1N aqueous HCl was added, and the mixture 
extracted with CH2Cl2 (3×). The combined organic layer was dried with MgSO4 and the solvent 
evaporated in vacuo. The residue was purified by CC or crystallization. 
Z-D-Ala-Thp-OMe (11a). The reaction of 1.020 g (2.32 mmol) of 10a in MeOH (10 mL) followed by 
CC (hexane/AcOEt 1:5) gave 775 mg (92%) of 11a. Colorless foam. IR (CHCl3): 3520m, 3330w, 3020w, 
3000m, 2960m, 2860m, 1740s, 1700s, 1500s, 1465w, 1455m, 1435w, 1380w, 1350w, 1320m, 1305m, 
1290m, 1230s, 1155w, 1140m, 1115m, 1070m, 1030w, 1015w, 1000w, 910w, 880w, 840w, 700m. 
1H-NMR (CDCl3): 7.35–7.27 (m, 5 arom. H); 6.79 (s, 1 NH); 5.36 (d, J = 7.3, 1 NH); 5.15, 5.10 (2d, JAB = 
12.1, PhCH2O); 4.27 (quint, J = 7.1, HC(2) of Ala); 3.81–3.72 (m, 2 H of –CH2OCH2–); 3.70 (s, MeO); 
3.62–3.48 (m, 2 H of –CH2OCH2–); 2.21–2.10, 1.96–1.89 (2m, –CH2CCH2–); 1.37 (d, J = 7.1, Me of Ala). 
13C-NMR (CDCl3): 173.2, 172.0 (2s, 2 C=O); 156.4 (s, OCON); 136.0 (s, 1 arom. C); 128.6, 128.4, 128.1 
(3d, 5 arom. CH); 67.3, 63.3 (2t, PhCH2O, –CH2OCH2–); 56.5 (s, C(4’)); 52.6 (s, MeO); 50.2 (d, HC(2) 
of Ala); 32.6, 32.5 (2t, –CH2CCH2–); 17.5 (q, Me of Ala). ESI-MS: 387 (100, [M+Na]
+). [α21D] +22.6 (c 
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1.045).  
Fmoc-D-Ala-Tht-OMe (11b). The reaction of 659 mg (1.21 mmol) of 10b in MeOH (5 mL) followed by 
CC (hexane/AcOEt 1:2) gave 534 mg (94%) of 11b. Colorless foam. IR (CHCl3): 3430m, 3340w, 3060w, 
3010m, 2950m, 1735s, 1695s, 1505s, 1465w, 1450m, 1435m, 1380w, 1350w, 1320m, 1280m, 1220s, 
1110w, 1075m, 1060m, 1020w, 930w, 710m, 670m. 1H-NMR (CDCl3): 7.75, 7.57 (2d, J = 7.4, 4 
Fmoc-H); 7.39, 7.29 (2t, J = 7.4, 4 Fmoc-H); 6.77 (s, 1 NH); 5.50 (d, J = 7.7, 1 NH); 4.40 (d, J = 6.7, 
Fmoc-CH2); 4.35–4.27 (m, HC(2) of Ala); 4.20 (t, J = 6.8, Fmoc-C(9)H); 3.68 (s, MeO); 2.74–2.63, 
2.55–2.45, 2.33–2.15 (3m, 4 CH2); 1.37 (d, J = 6.9, Me of Ala). 
13C-NMR (CDCl3): 173.4, 171.9 (2s, 2 
C=O); 156.4 (s, OCON); 143.6, 141.3 (2s, 4 arom. C); 127.8, 127.1, 125.0, 120.1 (4d, 8 arom. CH); 67.3 
(t, Fmoc-CH2); 58.1 (s, C(4’)); 52.5 (q, MeO); 50.3 (d, HC(2) of Ala); 47.0 (d, Fmoc-C(9)H); 33.3 (t, 
–CH2CCH2–); 23.5, 23.4 (2t, –CH2SCH2–); 18.0 (q, Me of Ala). ESI-MS: 491 (100, [M+Na]
+). [α21D] 
+12.1 (c 0.962).  
Z-D-Ala-Pip-OMe (11c). A solution of 1.742 g (2.64 mmol) of 10c in MeOH (20 mL) was reacted with 
HCl gas. Then, the solvent was evaporated under vacuum, the residue was dissolved in CH2Cl2 and 
washed with 1N aqueous NaOH. The aqueous phase was extracted with CH2Cl2, the combined organic 
phase was dried (MgSO4) and the solvent evaporated. CC (Et2O/AcOEt 1:4) gave 650 mg (68%) of 11c. 
Colorless foam. 1H-NMR (CDCl3): 7.35–7.25 (m, 5 arom. H, 1 NH); 5.70 (d-like, 1 NH); 5.11 (br. s, 
PhCH2O); 4.35–4.25 (m, HC(2) of Ala); 3.75 (br. s, 1 NH); 3.67 (s, MeO); 2.99–2.70 (m, –CH2NCH2–); 
2.10–2.00 (m, –CH2CCH2–); 1.38 (d, J = 7.0, Me of Ala). 
13C-NMR (CDCl3): 173.5, 172.2 (2s, 2 C=O); 
156.2 (s, OCON); 136.3 (s, 1 arom. C); 128.5, 128.2, 128.0 (3d, 5 arom. CH); 67.0 (t, PhCH2O); 57.2 (s, 
C(4’)); 52.5 (q, MeO); 47.1 (d, HC(2) of Ala); 41.5 (t, –CH2NCH2–); 32.0 (t, –CH2CCH2–); 18.2 (q, Me 
of Ala). CI-MS: 364 (100, [M+1]+), 256 (32).  
Z-D-Ala-Pip(Fmoc)-OMe (11d). A solution of 1.846 g (2.79 mmol) of 10c in MeOH (20 mL) was 
reacted with HCl gas. Then, the solvent was evaporated under vacuum, the residue was dissolved in 
CH2Cl2 (20 mL), cooled to 0 °C, and 1.56 mL (11.2 mmol) Et3N and 1.446 g (5.59 mmol) of 
Fmoc-chloride were added. After stirring for 14 h at rt, the mixture was washed with 1N HCl. The 
aqueous phase was extracted with CH2Cl2, the combined organic phase was dried (MgSO4) and the 
solvent evaporated. CC (hexane/AcOEt 1:2) gave 1.236 g (76%) of 11d. Colorless foam. IR (CHCl3): 
3430w, 3070w, 3000w, 2960w, 2870w, 1740m, 1695s, 1500m, 1480m, 1450m, 1435m, 1350w, 1335w, 
1280m, 1270m, 1240m, 1205m, 1155m, 1135w, 1095w, 1065m, 1050m, 1040w, 1030w, 925w. 1H-NMR 
(CDCl3): 7.67, 7.47 (2d, J = 7.4, 4 Fmoc-H); 7.31 (t, J = 7.4, 2 Fmoc-H); 7.25–7.17 (m, 7 arom. H); 6.69 
(s, 1 NH); 5.24 (d, J = 7.1, 1 NH); 5.05, 4.09 (2d, JAB = 12.2, PhCH2O); 4.40–4.32, 4.17–4.12, 3.83–3.57 
(3m, Fmoc-CH2, Fmoc-C(9)H, HC(2) of Ala, 2 H of –CH2NCH2–); 3.60 (s, MeO); 2.99–2.89 (m, 2 H of 
–CH2NCH2–); 1.86–1.79 (m, –CH2CCH2–); 1.27 (d, J = 7.0, Me of Ala). 
13C-NMR (CDCl3): 172.9, 172.0 
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(2s, 2 C=O); 156.3, 154.8 (2s, 2 OCON); 143.9, 141.3, 135.9 (3s, 5 arom. C); 128.5, 128.3, 128.0, 127.6, 
127.0, 124.8, 119.9 (7d, 13 arom. CH); 67.2 (t, PhCH2O, Fmoc-CH2); 57.2 (s, C(4’)); 52.5 (q, MeO); 50.3, 
47.3 (2d, HC(2) of Ala, Fmoc-C(9)H); 39.5 (t, –CH2NCH2–); 31.7 (t, –CH2CCH2–); 17.3 (q, Me of Ala). 
ESI-MS: 608 (100, [M+Na]+). [α21D] +10.4 (c 1.024).  
The same product was obtained from 11c (578 mg, 1.59 mmol) in CH2Cl2 (10 mL) at 0 °C by treatment 
with 270 µL (1.94 mmol) Et3N and Fmoc-chloride (450 mg, 1.74 mmol). After stirring for 14 h at rt and 
purification by CC (hexane/AcOEt 1:2), 811 mg (87%) of 11d were isolated. 
Fmoc-D-Ala-Pip(Z)-OMe (11f). A solution of 1.371 g (1.83 mmol) of 10d in MeOH (15 mL) was 
reacted with HCl gas. Then, the solvent was evaporated under vacuum, the residue was dissolved in 
CH2Cl2 (15 mL), cooled to 0 °C, and 1.10 mL (7.9 mmol) Et3N and 624 mg (3.66 mmol) of Z-chloride 
were added. After stirring for 14 h at rt, the mixture was washed with 1N HCl. The aqueous phase was 
extracted with CH2Cl2, the combined organic phase was dried (MgSO4) and the solvent evaporated. CC 
(hexane/AcOEt 1:2) gave 882 g (76%) of 11f. Colorless foam. IR (CHCl3): 3430w, 3330w, 3060w, 3000m, 
2960w, 2870w, 1740m, 1690s, 1510m, 1500m, 1480w, 1450m, 1430m, 1385w, 1365w, 1355w, 1320m, 
1280m, 1265m, 1230m, 1150w, 1135w, 1075m, 1020w, 1000w, 975w, 925w. 1H-NMR (CDCl3): 7.68, 
7.47 (2d, J = 7.4, 4 Fmoc-H); 7.33–7.17 (m, 9 arom. H); 6.68 (s, 1 NH); 5.30 (d, J = 7.5, 1 NH); 5.03 (s, 
PhCH2O); 4.32 (d, J = 6.8, Fmoc-CH2); 4.19–4.08 (m, HC(2) of Ala); 4.11 (t, J = 6.8, Fmoc-C(9)H); 
3.83–3.70 (m, 2 H of –CH2NCH2–); 3.60 (s, MeO); 3.13–3.01 (m, 2 H of –CH2NCH2–); 1.98–1.89 (m, 
–CH2CCH2–); 1.27 (d, J = 7.0, Me of Ala). 
13C-NMR (CDCl3): 173.0, 172.1 (2s, 2 C=O); 156.2, 155.0 (2s, 
2 OCON); 143.5, 141.2, 136.5 (3s, 5 arom. C); 128.4, 128.0, 127.8, 127.7, 127.0, 124.8, 120.0 (7d, 13 
arom. CH); 67.2 (t, PhCH2O, Fmoc-CH2); 57.3 (s, C(4’)); 52.5 (q, MeO); 50.2, 47.0 (2d, HC(2) of Ala, 
Fmoc-C(9)H); 39.5 (t, –CH2NCH2–); 31.9, 31.7 (2t, –CH2CCH2–); 17.8 (q, Me of Ala). ESI-MS: 608 (100, 
[M+Na]+). Anal. Calcd for C33H35N3O7 (585.66): C 67.68, H 6.02, N 7.17. Found: C 67.19, H 6.09, N 7.07. 
[α21D] +12.1 (c 1.061). 
 
Synthesis of dipeptide Z-D-Ala-Pip(Boc)-OMe (11e). To a solution of 11d (1.183 g, 1.97 mmol) in 
CH2Cl2 (5 mL) was added piperidine (0.5 mL). The mixture was stirred at rt for 1 h, the solvent 
evaporated, the residue dissolved in CH2Cl2, and 860 mg (3.94 mmol) Boc-anhydride and 550 µL (3.94 
mmol) Et3N were added. After stirring for 14 h at rt, the solvent was evaporated and the residue purified 
by CC (hexane/AcOEt 1:2) yielding 643 mg (70%) of 11e. Colorless foam. IR (CHCl3): 3430m, 3340w, 
3060w, 3000m, 2980m, 1730s, 1680s, 1510m, 1500s, 1450m, 1430m, 1390m, 1370m, 1320m, 1280s, 
1240s, 1170m, 1150m, 1095w, 1065m, 1030w, 1010w, 975w, 930w, 860w. 1H-NMR (CDCl3): 7.34–7.29 
(m, 5 arom. H); 6.86 (s, 1 NH); 5.46 (d, J = 7.5, 1 NH); 5.12, 5.07 (2d, JAB = 12.2, PhCH2O); 4.29–4.20, 
3.85–3.71 (2m, HC(2) of Ala, 2 H of –CH2NCH2–); 3.67 (s, MeO); 3.04–2.91 (m, 2 H of –CH2NCH2–); 
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2.02–1.85 (m, –CH2CCH2–); 1.46 (s, Me3C); 1.36 (d, J = 7.0, Me of Ala). 
13C-NMR (CDCl3): 173.2, 
172.1 (2s, 2 C=O); 156.2, 154.3 (2s, 2 OCON); 135.9 (s, 1 arom. C); 128.5, 128.2, 127.9 (3d, 5 arom. 
CH); 79.7 (s, Me3C); 67.1 (t, PhCH2O); 57.3 (s, C(4’)); 52.4 (q, MeO); 50.2 (d, HC(2) of Ala); 39.1 (t, 
–CH2NCH2–); 31.9, 31.6 (2t, –CH2CCH2–); 28.3 (q, Me3C); 17.6 (q, Me of Ala). ESI-MS: 486 (100, 
[M+Na]+). Anal. Calcd for C23H33N3O7 (463.53): C 59.60, H 7.18, N 9.07. Found: C 59.33, H 7.29, N 8.76. 
[α21D] +11.5 (c 0.989). 
 
Selective deprotection of the terminal amino group of dipeptide esters 11a,b.  
H-D-Ala-Thp-OMe (12a). To a solution of dipeptide 11a (167 mg, 0.458 mmol) in MeOH (3 mL) was 
added 16.7 mg of Pd/C (10%). This mixture was stirred under an H2-atmosphere at rt until disappearance 
of 11a (TLC). After filtration via Celite, the solvent of the filtrate was evaporated and the residue dried in 
HV: 85 mg (81%) of 12a. White powder. 1H-NMR (CF3CO2D): 4.52 (q, J = 7.0, HC(2) of Ala); 
4.39–4.31, 4.18–3.99 (2m, –CH2OCH2–); 3.45 (s, MeO); 2.62–2.53, 2.06–1.98 (2m, –CH2CCH2–); 1.70 (d, 
J = 7.0, Me of Ala). 13C-NMR (CF3CO2D): 172.8, 171.7 (2s, 2 C=O); 62.1 (t, –CH2OCH2–); 55.6 (s, 
C(4’)); 54.0 (s, MeO); 50.3 (d, HC(2) of Ala); 34.6, 33.5 (2t, –CH2CCH2–); 18.2 (q, Me of Ala). CI-MS: 
461 (35, [2M+1]+), 231 (100, [M+1]+). 
H-D-Ala-Tht-OMe (12b). The dipeptide 11b (120 mg, 0.256 mmol) was dissolved in piperidine (3 mL) 
at rt. After 10 min, the precipitate was filtered and washed with AcOEt to give 48 mg (76%) of 12b. 
White powder. 1H-NMR (CF3CO2D): 4.50 (q, J = 7.0, HC(2) of Ala); 3.41 (s, MeO); 2.63–2.55, 
2.23–2.18, 2.02–1.95, 1.87–1.79 (4m, 4 CH2); 1.68 (d, J = 7.0, Me of Ala). 
13C-NMR (CF3CO2D): 174.8, 
174.3 (2s, 2 C=O); 60.0 (s, C(4’)); 52.6 (s, MeO); 48.4 (d, HC(2) of Ala); 37.8, 36.6 (2t, –CH2CCH2–); 
24.4, 23.4 (2t, –CH2SCH2–); 20.8 (q, Me of Ala). CI-MS: 461 (35, [2M+1]
+), 231 (100, [M+1]+). 
 
Synthesis of tripeptides 14 via coupling of dipeptides with aspartic acid derivatives.  
Z-Asp(OBn)-D-Ala-Thp-OMe (14a). To a solution of 11a (764 mg, 2.10 mmol) in MeOH (10 mL)/DMF 
(15 mL) was added Pd/C (10%, 38 mg) and the mixture was treated with H2 until the disappearance of 
11a (TLC). The catalyst was removed by filtration via Celite and MeOH was evaporated. To the 
remaining solution were added Z-Asp(OBn)-OH (13a, 900 mg, 2.52 mmol), PyBOP (1.312 g, 2.52 
mmol), and Et3N (700 µL, 3 mmol), and the mixture was stirred for 16 h at rt. Evaporation of the solvent, 
CC (Et2O/AcOEt 1:2), and crystallization from hexane/AcOEt/MeOH yielded 956 mg (80%) 14a. 
Colorless crystals; mp 127–128 °C. IR (CHCl3): 3420m, 3070w, 3030m, 3000m, 2960m, 2860w, 1760s, 
1715s, 1695s, 1680s, 1515s, 1505s, 1455m, 1445m, 1430w, 1405w, 1390m, 1355m, 1290m, 1260m, 
1190m, 1160m, 1145m, 1105m, 1075w, 1050m, 1030w, 1000w, 980w, 970w, 960w, 920w, 845w. 
1H-NMR (CDCl3): 7.28–7.21 (m, 10 arom. H); 6.92–6.88 (m, 2 NH); 5.93 (d, J = 8.4, 1 NH); 5.07–4.97 
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(m, 2 PhCH2O); 4.55–4.48 (m, HC(2) of Asp); 4.40 (quint, J = 7.3, HC(2) of Ala); 3.70–3.63, 3.56–3.51 
(2m, –CH2OCH2–); 3.61 (s, MeO); 3.05–2.70 (m, CH2 of Asp); 2.11–1.85 (m, –CH2CCH2–); 1.27 (d, J = 
7.0, Me of Ala). 13C-NMR (CDCl3): 173.3, 171.5, 170.7 (3s, 3 C=O); 156.1 (s, OCON); 135.6, 135.0 (2s, 
2 arom. C); 128.6, 128.4, 128.1, 128.0 (4d, 10 arom. CH); 67.5, 66.9 (2t, 2 PhCH2O); 63.3, 63.2 (2t, 
–CH2OCH2–); 56.6 (s, C(4’)); 52.4 (s, MeO); 51.4, 49.0 (2d, HC(2) of Ala, HC(2) of Asp); 35.9 (t, CH2 of 
Asp); 32.6, 32.2 (2t, –CH2CCH2–); 16.8 (q, Me of Ala). ESI-MS: 592 (100, [M+Na]
+). [α21D] +8.7 (c 
0.946). 
Fmoc-Asp(OtBu)-D-Ala-Tht-OMe (14b). To a solution of 11b (262 mg, 0.559 mmol) in DMSO (3 mL) 
was added piperidine (49 mg, 0.575 mmol) at rt. After 40 min, the residual piperidine was removed by 
distillation. Then, 232 mg (0.564 mmol) Fmoc-Asp(OtBu)-OH (13b) and 303 mg (0.583 mmol) PyBOP 
were added and the mixture stirred for 16 h at rt. The solvent was removed by distillation (high vacuum) 
and the residue purified by CC (hexane/AcOEt 1:3) to give 330 mg (92%) of 14b. Colorless foam. IR 
(CHCl3): 3420w, 3020w, 3000m, 2980m, 2950w, 1730s, 1715s, 1680s, 1505s, 1465w, 1450m, 1435m, 
1420w, 1405w, 1395w, 1370m, 1315m, 1280m, 1260m, 1155w, 1105w, 1080w, 1065m, 1050m, 1020w, 
930w, 920w, 900w, 880w, 855w, 840w, 820w. 1H-NMR (CDCl3): 7.76, 7.57 (2d, J = 7.4, 4 Fmoc-H); 7.40 
(t, J = 7.4, 2 Fmoc-H); 7.34–7.30 (m, 2 Fmoc-H); 6.88 (d, J = 7.6, 1 NH); 6.75 (s, 1 NH); 5.88 (d-like, br, 
1 NH); 4.51–4.43, 4.24–4.19 (2m, Fmoc-CH2, Fmoc-C(9)H, HC(2) of Asp, HC(2) of Ala); 3.68 (s, MeO); 
2.92–2.18 (m, CH2 of Asp, 4 CH2); 1.45 (s, Me3C); 1.35 (d, J = 7.0, Me of Ala). 
13C-NMR (CDCl3): 173.4, 
171.2, 170.9, 170.6 (4s, 4 C=O); 156.1 (s, OCON); 143.5, 141.2 (2s, 4 arom. C); 127.7, 127.0, 124.8, 
120.0 (4d, 8 arom. CH); 82.0 (s, Me3C); 67.3 (t, Fmoc-CH2); 58.1 (s, C(4’)); 52.4 (q, MeO); 51.4, 48.9, 
47.0 (3d, HC(2) of Ala, HC(2) of Asp, Fmoc-C(9)H); 37.1, 33.3, 33.2 (3t, CH2 of Asp, –CH2CCH2–); 
28.0 (q, Me3C); 23.4 (t, –CH2SCH2–); 16.8 (q, Me of Ala). ESI-MS: 662 (100, [M+Na]
+), 440 (47, 
[M–Fmoc+Na]+). [α21D] +5.2 (c 1.085).  
Z-Asp(OBn)-D-Ala-Pip(Boc)-OMe (14c). To a solution of 11e (545 mg, 1.18 mmol) in MeOH (10 
mL)/DMF (15 mL) was added Pd/C (10%, 47 mg) and the mixture was treated with H2 until the 
disappearence of 11e (TLC). The catalyst was removed by filtration via Celite and MeOH was evaporated. 
To the remaining solution were added Z-Asp(OBn)-OH (13a, 505 mg, 1.41 mmol), PyBOP (730 mg, 1.40 
mmol), and Et3N (200 µL, 1.4 mmol), and the mixture was stirred for 16 h at rt. Evaporation of the 
solvent and subsequent CC (Et2O/AcOEt 1:1) yielded 657 mg (84%) 14c. Colorless foam. IR (CHCl3): 
3420m, 3060w, 3020m, 3000m, 2970m, 1740s, 1715s, 1680s, 1515m, 1500m, 1495m, 1450m, 1430m, 
1390m, 1365m, 1355m, 1280m, 1270m, 1240m, 1170m, 1150m, 1070m, 1050w, 975w, 920w, 855w, 845w. 
1H-NMR (CDCl3): 7.35–7.26 (m, 10 arom. H); 6.92 (s, 1 NH); 6.87 (d, J = 7.3, 1 NH); 5.93 (d, J = 9.0, 1 
NH); 5.15–5.02 (m, 2 PhCH2O); 4.60–4.54 (m, HC(2) of Asp); 4.45 (quint, J = 7.3, HC(2) of Ala); 
3.82–3.75 (m, 2 H of –CH2NCH2–); 3.67 (s, MeO); 3.16–3.03, 2.84–2.76 (2m, 2 H of –CH2NCH2–, CH2 
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of Asp); 2.04–1.96 (m, –CH2CCH2–); 1.42 (s, Me3C); 1.32 (d, J = 7.0, Me of Ala). 
13C-NMR (CDCl3): 
173.4, 171.7, 171.6, 170.8 (4s, 4 C=O); 156.2, 154.6 (2s, 2 OCON); 135.7, 135.1 (2s, 2 arom. C); 128.7, 
128.5, 128.2, 127.9 (4d, 10 arom. CH); 79.8 (s, Me3C); 67.6, 67.0 (2t, 2 PhCH2O); 57.6 (s, C(4’)); 52.5 (q, 
MeO); 51.4, 49.1 (2d, HC(2) of Ala, HC(2) of Asp); 39.3, 35.9 (2t, –CH2NCH2–, CH2 of Asp); 32.0, 31.6 
(2t, –CH2CCH2–); 28.4 (q, Me3C); 16.9 (q, Me of Ala). ESI-MS: 691 (100, [M+Na]
+). [α21D] +7.8 (c 
0.992). 
Fmoc-Asp(OtBu)-D-Ala-Pip(Z)-OMe (14d). To a solution of 11f (250 mg, 0.472 mmol) in DMSO (4 
mL) was added piperidine (45 µL, 0.456 mmol) at rt. After 40 min, the residual piperidine was removed 
by distillation. Then, 194 mg (0.472 mmol) Fmoc-Asp(OtBu)-OH (13b) and 245 mg (0.471 mmol) 
PyBOP were added and the mixture stirred for 16 h at rt. The solvent was removed by distillation (high 
vacuum) and the residue purified by CC (hexane/AcOEt 1:3) to give 147 mg (44%) of 14d. Colorless 
foam. IR (CHCl3): 3450w, 3330w, 3060w, 3020w, 3000m, 2980m, 2950w, 1730s, 1710s, 1690s, 1515s, 
1505s, 1450m, 1430m, 1395w, 1370m, 1320m, 1280m, 1255m, 1245m, 1150m, 1105w, 1060m, 1020w, 
955w, 925w, 900w, 855w, 840w, 820w. 1H-NMR (CDCl3): 7.75, 7.56 (2d, J = 7.4, 4 Fmoc-H); 7.42–7.21 
(m, 9 arom. H); 6.97 (s, 1 NH); 6.89 (d, J = 7.6, 1 NH); 5.81 (d-like, 1 NH); 5.10 (s, PhCH2O); 4.50–4.41 
(m, HC(2) of Asp, HC(2) of Ala, Fmoc-CH2); 4.21 (t, J = 6.6, Fmoc-C(9)H); 3.89–3.73 (m, 2 H of 
–CH2NCH2–); 3.67 (s, MeO); 3.27–3.16 (m, 2 H of –CH2NCH2–); 2.98–2.87, 2.74–2.66 (2m, CH2 of 
Asp); 2.07–1.98 (m, –CH2CCH2–); 1.41 (s, Me3C); 1.35 (d, J = 7.1, Me of Ala). 
13C-NMR (CDCl3): 173.1, 
171.6, 170.7 (3s, 4 C=O); 156.1, 155.0 (2s, 2 OCON); 143.5, 143.4, 141.2, 136.6 (4s, 5 arom. C); 128.4, 
127.9, 127.8, 127.5, 127.0, 124.8, 120.0 (7d, 13 arom. CH); 82.0 (s, Me3C); 67.2, 67.1 (2t, PhCH2O, 
Fmoc-CH2); 57.4 (s, C(4’)); 52.4 (q, MeO); 51.4, 48.9, 47.0 (3d, HC(2) of Ala, HC(2) of Asp, 
Fmoc-C(9)H); 39.5, 37.0 (2t, –CH2NCH2–, CH2 of Asp); 32.0, 31.6 (2t, –CH2CCH2–); 27.9 (q, Me3C); 
16.9 (q, Me of Ala). ESI-MS: 779 (100, [M+Na]+). [α21D] +5.1 (c 1.097). 
 
Preparation of the zwitterionic tripeptides 15a–d. 
H-Asp-D-Ala-Thp-OMe (15a). To a solution of 14a (125 mg, 0.219 mmol) in MeOH (10 mL) was added 
Pd/C (10%, 15 mg) and the mixture was treated with H2 for 6 h. The catalyst was removed by filtration 
via Celite, MeOH was evaporated, and the residue dried (HV) to give 89 mg (98%) of 15a. Colorless 
powder; mp 129–131 °C. IR (KBr): 3460m, 3300m, 3060m, 2960m, 1745m, 1730m, 1695s, 1680s, 1665s, 
1645m, 1630m, 1580m, 1575m, 1565s, 1550s, 1540s, 1505w, 1495w, 1470m, 1450m, 1445m, 1430m, 
1400m, 1390m, 1385m, 1345w, 1335w, 1310w, 1290m, 1260m, 1230m, 1150m, 1100m, 1070m, 1030w, 
1015w, 1005w, 985w, 965w, 920w, 890w, 870w, 840w. 1H-NMR (CD3OD): 4.43–4.35 (m, HC(2) of Asp); 
4.09–404 (m, HC(2) of Ala); 3.79–3.65 (m, –CH2OCH2–); 3.68 (s, MeO); 2.71–2.56 (m, CH2 of Asp); 
2.17–1.89 (m, –CH2CCH2–); 1.37 (d, J = 7.1, Me of Ala). 
13C-NMR (CD3OD): 174.6, 173.6, 173.4, 168.6 
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(4s, 4 C=O); 62.2, 62.8 (2t, –CH2OCH2–); 56.4 (s, C(4’)); 51.4 (s, MeO); 50.8, 48.9 (2d, HC(2) of Ala, 
HC(2) of Asp); 36.7 (t, CH2 of Asp); 32.2, 31.6 (2t, –CH2CCH2–); 16.6 (q, Me of Ala). ESI-MS: 384 (27, 
[M+K]+), 368 (23, [M+Na]+), 346 (100, [M+1]+). [α21D] +31.3 (c 1.020). 
H-Asp-D-Ala-Tht-OMe (15b). To a solution of 50 mg (0.078 mmol) 14b in CH2Cl2 (1 mL) was added 
piperidine (100 µL, 1.01 mmol) and the mixture stirred for 30 min at rt. Then, the solvent and piperidine 
were evaporated and the residue purified by CC (CH2Cl2/MeOH/NH3(aq) 100:2.5:0.25) yielding 30 mg 
(92%) of H-Asp(OtBu)-D-Ala-Tht-OMe as a colorless foam. IR (CHCl3): 3440m, 3020w, 2980m, 2950w, 
1740s, 1730s, 1715s, 1695s, 1680s, 1660s, 1650s, 1510s, 1495m, 1480m, 1395w, 1370m, 1335w, 1330w, 
1320w, 1280s, 1260m, 1150s, 1085w, 1060w, 1015w, 950w, 940w, 930w, 840w. 1H-NMR (CDCl3): 7.94 
(d, J = 7.1, 1 NH); 7.21 (s, 1 NH); 4.45 (quint, J = 7.0, HC(2) of Ala); 3.64 (s, MeO); 3.64–3.57 (m, 
HC(2) of Asp); 2.79–2.64, 2.55–2.43, 2.30–2.05 (3m, CH2 of Asp, 4 CH2); 1.89 (s, NH2); 1.39 (s, Me3C); 
1.35 (d, J = 7.0, Me of Ala). 13C-NMR (CDCl3): 173.3, 172.6, 170.7, 169.8 (4s, 4 C=O); 80.4 (s, Me3C); 
57.1 (s, C(4’)); 52.4 (q, MeO); 50.9, 47.5 (2d, HC(2) of Ala, HC(2) of Asp); 40.2 (t, CH2 of Asp); 32.2 (t, 
–CH2CCH2–); 27.1 (q, Me3C); 22.5, 22.4 (2t, –CH2SCH2–); 15.9 (q, Me of Ala). ESI-MS: 440 (38, 
[M+Na]+), 418 (100, [M+1]+). [α21D] +21.1 (c 1.010). A solution of 85 mg (0.203 mmol) of the product in 
TFA (1 mL) was stirred for 2 h. After evaporation of TFA and drying of the residue (HV), ca. 100 mg of 
15b, still containing TFA, were obtained. 1H-NMR (CD3OD): 4.48–4.40, 4.23–4.17 (2 m, HC(2) of Asp, 
HC(2) of Ala); 3.67 (s, MeO); 3.05–2.75, 2.55–2.08 (2m, CH2 of Asp, 4 CH2); 1.37 (d, J = 7.1, Me of 
Ala). 13C-NMR (CD3OD): 175.4, 174.4, 172.9, 169.0 (4s, 4 C=O); 59.7 (s, C(4’)); 51.4 (q, MeO); 49.3, 
49.0 (2d, HC(2) of Ala, HC(2) of Asp); 36.0, 34.9, 34.2 (3t, CH2 of Asp, –CH2CCH2–); 24.3, 24.2 (2t, 
–CH2SCH2–); 17.8 (q, Me of Ala). 
H-Asp-D-Ala-Pip(Boc)-OMe (15c). To a solution of 14c (252 mg, 0.377 mmol) in MeOH (10 mL) was 
added Pd/C (10%, 35 mg) and the mixture was treated with H2 for 7 h. The catalyst was removed by 
filtration via Celite, MeOH was evaporated, and the residue dried (HV) to give 167 mg (100%) of 15c. 
Colorless powder; mp 137–140 °C. IR (KBr): 3400m, 3250m, 3060m, 2985m, 1740m, 1730m, 1690s, 
1680s, 1670s, 1635m, 1615m, 1570m, 1550m, 1540m, 1515m, 1505m, 1485m, 1470m, 1465m, 1455m, 
1445m, 1430s, 1390m, 1370m, 1330w, 1280m, 1240m, 1170m, 1150m, 1090w, 1070m, 1010w, 975w, 
920w, 850w, 810w. 1H-NMR (CD3OD): 4.40–4.33 (m, HC(2) of Asp); 4.10–4.04 (m, HC(2) of Ala), 
3.83–3.74 (m, 2 H of –CH2NCH2–); 3.67 (s, MeO); 3.26–3.12 (m, 2 H of –CH2NCH2–); 2.74–2.54 (m, 
CH2 of Asp); 2.12–1.89 (m, –CH2CCH2–); 1.46 (s, Me3C); 1.37 (d, J = 7.1, Me of Ala). 
13C-NMR 
(CD3OD): 176.0, 175.1, 170.4, 170.1 (4s, 4 C=O); 156.4 (s, OCON); 81.3 (s, Me3C); 58.7 (s, C(4’)); 53.0 
(q, MeO); 52.3, 50.5 (2d, HC(2) of Ala, HC(2) of Asp); 41.2, 40.6 (2t, –CH2NCH2–); 38.2 (t, CH2 of 
Asp); 33.1, 32.3 (2t, –CH2CCH2–); 28.7 (q, Me3C); 18.0 (q, Me of Ala). ESI-MS: 467 (54, [M+Na]
+), 445 
(100, [M+1]+). [α21D] +18.8 (c 1.020). 
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H-Asp-D-Ala-Pip(Z)-OMe (15d). To a solution of 797 mg (1.05 mmol) 14d in CH2Cl2 (5 mL) was added 
piperidine (5 mL) and the mixture stirred for 30 min at rt. Then, the solvent and piperidine were 
evaporated and the residue purified by CC (CH2Cl2/MeOH/NH3(aq) 100:3:0.3) yielding 515 mg (91%) of 
H-Asp(OtBu)-D-Ala-Pip(Z)-OMe as a colorless foam. IR (CHCl3): 3360m, 3060w, 3000m, 2980m, 2950w, 
1740m, 1730m, 1710m, 1705m, 1690s, 1680s, 1520m, 1505m, 1470w, 1450m, 1435m, 1395w, 1370m, 
1330w, 1280m, 1245m, 1150m, 1095m, 1070m, 1020w, 970w, 925w, 890w, 850w. 1H-NMR (CDCl3): 
7.86 (d, J = 8.0, 1 NH); 7.38–7.28 (m, 5 arom. H); 7.23 (s, 1 NH); 5.11 (s, PhCH2O); 4.55–4.44 (m, 
HC(2) of Ala); 3.90–3.78 (m, 2 H of –CH2NCH2–); 3.71 (s, MeO); 3.62–3.58 (m, HC(2) of Asp); 
3.35–3.20 (m, 2 H of –CH2NCH2–); 2.87–2.65 (m, CH2 of Asp); 2.08–2.01 (m, –CH2CCH2–); 1.86 (s, 
NH2); 1.40 (s, Me3C); 1.38 (d, J = 7.2, Me of Ala). 
13C-NMR (CDCl3): 174.0, 173.3, 172.1, 171.3 (4s, 4 
C=O); 155.1 (s, OCON); 136.7 (s, 1 arom. C); 128.5, 128.0, 127.9 (3d, 5 arom. CH); 81.6 (s, Me3C); 67.2 
(t, PhCH2O); 57.4 (s, C(4’)); 52.5 (q, MeO); 51.6, 48.5 (2d, HC(2) of Ala, HC(2) of Asp); 40.2, 39.7 (2t, 
–CH2NCH2–, CH2 of Asp); 31.8 (t, –CH2CCH2–); 28.1 (q, Me3C); 16.8 (q, Me of Ala). ESI-MS: 557 (22, 
[M+Na]+), 535 (100, [M+1]+). [α21D] +22.3 (c 0.990). A solution of 67 mg (0.125 mmol) of the product in 
TFA (1 mL) was stirred for 1.5 h, whereby the color of the solution turned to pale brown. After 
evaporation of TFA and drying of the residue (HV), it was dissolved in MeOH. Evaporation of the 
solvents and drying in HV yielded 82 mg of 15d, which contained still TFA. 1H-NMR (CD3OD): 
7.35–7.29 (m, 5 arom. H); 5.11 (s, PhCH2O); 4.41–4.33, 4.21–4.16 (2m, HC(2) of Asp, HC(2) of Ala); 
3.88–3.82 (m, 2 H of –CH2NCH2–); 3.66 (s, MeO); 3.31–3.20 (m, 2 H of –CH2NCH2–); 2.99–2.82 (m, 
CH2 of Asp); 2.15–1.93 (m, –CH2CCH2–); 1.37 (d, J = 7.1, Me of Ala). 
13C-NMR (CD3OD): 173.5, 173.4, 
171.1, 167.4 (4s, 4 C=O); 155.3 (s, OCON); 136.5 (s, 1 arom. C); 128.1, 127.7, 127.4 (3d, 5 arom. CH); 
66.9 (t, PhCH2O); 57.2 (s, C(4’)); 51.4 (q, MeO); 49.4, 49.1 (2d, HC(2) of Ala, HC(2) of Asp); 39.3, 39.2 
(2t, –CH2NCH2–); 34.4 (t, CH2 of Asp); 31.5, 30.7 (2t, –CH2CCH2–); 16.5 (q, Me of Ala). ESI-MS: 501 
(13, [M+Na]+), 479 (100, [M+1]+). 
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